Eficacia de lutecio-177 DOTATATE/TOC en pacientes con tumores neuroendocrinos bien diferenciados en estado avanzado. Ensayo clínico fase II
DOI:
https://doi.org/10.35509/01239015.132Palabras clave:
Tumores neuroendocrinos, Receptores de somatostatina, Lutecio, Medicina nuclear, RadiofármacosResumen
Introducción: En 2009, el Instituto Nacional de Cancerología (INC) elaboró el 177Lu-DOTATATE/TOC. El propósito del estudio fue demostrar la eficacia de estos radiopéptidos en el tratamiento paliativo de pacientes con tumores neuroendocrinos (TNE) avanzados inoperables (metastásicos o localmente avanzados) y en progresión.
Métodos: Ensayo clínico abierto fase II de un solo brazo en 13 pacientes adultos con TNE grado 1 o 2, con expresión de receptores de somatostatina en lesiones blanco demostrada por captación Krenning 3 o 4 en 99mTc-HYNIC TOC. Los pacientes fueron tratados con 177Lu-DOTATATE o 177Lu-DOTATOC (según disponibilidad) a una actividad acumulativa proyectada de 600-800 mCi dividida en 3-4 dosis cada 6-9 semanas comenzando siempre con una actividad fija de 200 mCi y dosimetría con la primera dosis. El desenlace primario fue la respuesta objetiva calculada 6 y 12 meses después de la última dosis del tratamiento.
Resultados: Se incluyeron 13 pacientes (7 mujeres) de 63 ± 11,6 años con TNE avanzado inoperable y en progresión. La actividad final administrada fue de 800 mCi, 600 mCi, 400 mCi y 200 mCi en 4, 7, 1 y 1 pacientes, respectivamente. La tasa de control de enfermedad a 6 y 12 meses fue de 69,2% y 45,5%, respectivamente, logrando únicamente enfermedad estable. Fallecieron 7 pacientes, 2 de ellos en los primeros 6 meses. La mediana de supervivencia global a partir de la última dosis del radiopéptido fue de 15,7 meses.
Conclusiones: Se corroboró la eficacia y la seguridad del tratamiento con los radiopéptidos en NETs avanzados.
Referencias bibliográficas
Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, et al. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. J Nucl Med [Internet]. 2011;52(12):1864–70. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22072704
Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017 Jan;376(2):125–35.
Pavel M, O’Toole D, Costa F, Capdevila J, Gross D, Kianmanesh R, et al. ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. Neuroendocrinology. 2016;103(2):172–85.
Shah MH, Goldner WS, Halfdanarson TR, Bergsland E, Berlin JD, Halperin D, et al. NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. J Natl Compr Canc Netw. 2018 Jun;16(6):693–702.
Delgado N, Martinez M, Reyes A de los, Llamas A. Preliminary results of the evaluation of 99mTc-EDDA/HYNIC-Tyr3- octeotride prepared from lyophilized kits vs 111 In-DTPA-octeotride with SPECT images in patients with metastatic neuroendocrine tumors in the National Cancer Institute of Bogota-Colombia [Internet]. International Atomic Energy Agency (IAEA); 2007. Available from: http://inis.iaea.org/search/search.aspx?orig_q=RN:39019789
Delgado N, Rada J, Villamil C, Llamas-Olier A, De los Reyes A, Martínez MC. Elaboración de un kit de [177Lu-DOTA-Tyr3] Octreotate calidad farmacéutica para ser administrado en terapia de tumores neuroendocrinos metastásicos en pacientes del Instituto Nacional de Cancerología. In: XI Congreso Colombiano de Medicina Nuclear. 2013.
Velikyan I, Sundin A, Sorensen J, Lubberink M, Sandstrom M, Garske-Roman U, et al. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification. J Nucl Med. 2014 Feb;55(2):204–10.
Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012 Jul;9(7):671–5.
Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF, et al. MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med. 1999 Feb;40(2):37S-61S.
Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005 Jun;46(6):1023–7.
Barone R, Borson-Chazot F, Valkema R, Walrand S, Chauvin F, Gogou L, et al. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med. 2005 Jan;46 Suppl 1:99S-106S.
Thames HD, Ang KK, Stewart FA, van der Schueren E. Does incomplete repair explain the apparent failure of the basic LQ model to predict spinal cord and kidney responses to low doses per fraction? Int J Radiat Biol. 1988 Jul;54(1):13–9.
Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs [Internet]. 1992;10(4):239–53. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1487397
Eisenhauer E a, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer [Internet]. 2009;45(2):228–47. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19097774
Yanez B Lis C, Beaumont J, Cella D PT. The FACT-G7: a rapid version of the functional assessment of cancer therapy-general (FACT-G) for monitoring symptoms and concerns in oncology practice and research. Ann Oncol. 2013;24(4):1073–8.
Sánchez R Ortíz N BM. Análisis de la validez de contenido de la escala FACT-G mediante técnicas de escalamiento multidimensional. Rev Colomb Cancerol. 2010;14(4):225–33.
Cives M, Strosberg J. An update on gastroenteropancreatic neuroendocrine tumors. Oncology (Williston Park). 2014 Sep;28(9):749-756,758.
Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 2017 Oct;3(10):1335–42.
Hauso O, Gustafsson BI, Kidd M, Waldum HL, Drozdov I, Chan AKC, et al. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer. 2008 Nov;113(10):2655–64.
Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, Diaz-Perez JA, Martinez Del Prado MP, Alonso Orduna V, et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol Off J Eur Soc Med Oncol. 2010 Sep;21(9):1794–803.
Fierro-Maya L, Prieto C, Garavito G, González A, Muleth Y, Carreño JA. Resultados del tratamiento multidisciplinario de tumores neuroendocrinos de intestino delgado. Rev Colomb Cancerol. 2018;22(3):105–11.
Modlin I OK Jensen R, Herder W, Thakker R, Caplin M, Dellefave G, Kaltsas G, Krenning E, Moss S, Nilsson O, Rindi G, Salazar R, Ruszniewsku P, Sundin A CD. Gastroenteropancreatic Neuroendocrine Tumors. Lancet Oncol. 2008;9:61–72.
Valkema R. JM Breeman WA., Kooij P., Pieternella J., et al BW. Phase I Study of Peptide Receptor Radionuclide Therapy with [111In-DTPA0] Octreótide: The Rotterdam Experience. Semin Nucl Med. 2002;XXXII(2):110–22.
Ezziddin S, Khalaf F, Vanezi M, Haslerud T, Mayer K, Al Zreiqat A, et al. Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2014 May;41(5):925–33.
Kwekkeboom DJ, Bakker WH, Kam BL, Teunissen JJM, Kooij PPM, de Herder WW, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate. Eur J Nucl Med Mol Imaging [Internet]. 2003;30(3):417–22. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1998890&tool=pmcentrez&rendertype=abstract
Kwekkeboom DJ, De Herder WW, Kam BL, Van Eijck CH, Van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177Lu- DOTA0,Tyr3]octreotate: Toxicity, efficacy, and survival. J Clin Oncol. 2008;26(13):2124–30.
Paganelli G, Sansovini M, Ambrosetti A, S S, Monti M, Scarpi E, et al. 177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study. Eur J Nucl Med Mol Imaging [Internet]. 2014;41:1845–54. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L53044788
Adunlin G, Cyrus JWW, Dranitsaris G. Correlation between progression-free survival and overall survival in metastatic breast cancer patients receiving anthracyclines, taxanes, or targeted therapies: a trial-level meta-analysis. Breast Cancer Res Treat. 2015 Dec;154(3):591–608.
Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, de Herder WW, Feelders RA, et al. Pitfalls in the response evaluation after peptide receptor radionuclide therapy with [(177)Lu-DOTA(0),Tyr(3)]octreotate. Endocr Relat Cancer. 2017 May;24(5):243–51.
Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011 Feb;364(6):514–23.
Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet (London, England). 2016 Mar;387(10022):968–77.
Raymond E, Dahan L, Raoul J-L, Bang Y-J, Borbath I, Lombard-Bohas C, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011 Feb;364(6):501–13.
Jimenez-Fonseca P, Krug S, Tamagno G, Fierro Maya F, Monleon Getino A, Rodriguez Casado CI, et al. Identifying Prognostic Factors for Well-Differentiated Metastatic Pancreatic Neuroendocrine Tumours: A Retrospective International Multicentre Cohort Study. Neuroendocrinology. 2018;107(4):315–23.
Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol [Internet]. 2008;26(13):2124–30. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18445841
Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, Feelders RA, de Herder WW, et al. Long-Term Efficacy, Survival, and Safety of [(177)Lu-DOTA(0),Tyr(3)]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors. Clin Cancer Res. 2017 Aug;23(16):4617–24.
Hope TA, Abbott A, Colucci K, Bushnell DL, Gardner L, Graham WS, et al. NANETS/SNMMI Procedure Standard for Somatostatin Receptor-Based Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE. J Nucl Med. 2019 Jul;60(7):937–43.
Abbott A, Sakellis CG, Andersen E, Kuzuhara Y, Gilbert L, Boyle K, et al. Guidance on (177)Lu-DOTATATE Peptide Receptor Radionuclide Therapy from the Experience of a Single Nuclear Medicine Division. J Nucl Med Technol. 2018 Sep;46(3):237–44.
Sandstrom M, Garske-Roman U, Granberg D, Johansson S, Widstrom C, Eriksson B, et al. Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment. J Nucl Med. 2013 Jan;54(1):33–41.
Cremonesi M. FM Tosi G., and Paganelli G BL. Dosimetry in peptide radionuclide receptor therapy: A review. J Nucl Med. 2006;47(9):1467–75.
Teunissen JJM, Kwekkeboom DJ, Krenning EP. Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate. J Clin Oncol [Internet]. 2004;22(13):2724–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15226340
Hope TA, Bodei L, Chan JA, El-Haddad G, Fidelman N, Kunz PL, et al. NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of (177)Lu-DOTATATE Peptide Receptor Radionuclide Therapy. J Nucl Med. 2020 Feb;61(2):222–7.
Cómo citar
Descargas
Descargas
Publicado
Número
Sección
Licencia
Todos los derechos reservados.
